TFEB-mediated transcriptional upregulation of lysosomal genes as a therapeutic strategy for AD

Molecular Mechanism and Rationale

The transcription factor EB (TFEB) represents a master regulatory node in cellular proteostasis, functioning as the primary coordinator of the Coordinated Lysosomal Expression and Regulation (CLEAR) network. This helix-loop-helix leucine zipper transcription factor orchestrates the expression of over 500 genes involved in lysosomal biogenesis, autophagy, and cellular clearance mechanisms. In Alzheimer’s disease (AD), the progressive accumulation of amyloid-β (Aβ) peptides and hyperphosphorylated tau proteins overwhelms the cellular clearance machinery, leading to neuronal dysfunction and death. TFEB activation offers a comprehensive therapeutic strategy by simultaneously enhancing multiple clearance pathways.

Under physiological conditions, TFEB activity is tightly regulated through phosphorylation-dependent nuclear-cytoplasmic shuttling. The mechanistic target of rapamycin complex 1 (mTORC1) phosphorylates TFEB at serine residues 142 and 211, promoting its cytoplasmic sequestration through interaction with 14-3-3 proteins. Additionally, extracellular signal-regulated kinase 2 (ERK2) phosphorylates TFEB at serine 142, while glycogen synthase kinase 3β (GSK3β) targets serine 134 and serine 138, collectively maintaining TFEB in an inactive cytoplasmic state. Lysosomal stress, nutrient starvation, or pharmacological intervention can reverse these phosphorylation events, leading to TFEB dephosphorylation by protein phosphatase 2A (PP2A) and subsequent nuclear translocation.

Upon nuclear entry, TFEB binds to Coordinated Lysosomal Expression and Regulation (CLEAR) elements—E-box-like sequences (GTCACGTGAC)—present in the promoter regions of target genes. These include essential lysosomal hydrolases such as cathepsins B, D, and L, β-hexosaminidase subunits HEXA and HEXB, and critical membrane proteins including LAMP1, LAMP2, and the vacuolar ATPase subunits that maintain lysosomal acidification. TFEB also upregulates autophagy-related genes such as ATG9B, WIPI1, and MAP1LC3B, creating a coordinated enhancement of both autophagosome formation and lysosomal degradative capacity.

Preclinical Evidence

Extensive preclinical validation supports TFEB activation as a viable therapeutic strategy for AD. In 5xFAD transgenic mice, which express five familial AD mutations and develop aggressive amyloid pathology by 4-6 months of age, adeno-associated virus (AAV)-mediated TFEB overexpression demonstrated remarkable efficacy. Stereotactic injection of AAV9-TFEB into the hippocampus resulted in 45-65% reduction in cortical Aβ plaque burden and 40-50% decrease in soluble Aβ42 levels as measured by enzyme-linked immunosorbent assay (ELISA). Behavioral improvements were equally impressive, with treated mice showing 60% improvement in Morris water maze performance and restored contextual fear conditioning responses.

In APP/PS1 double transgenic mice, pharmacological TFEB activation using the salt-inducible kinase (SIK) inhibitor YKL-05-099 produced dose-dependent improvements in cognitive function. Treatment with 10 mg/kg daily for 12 weeks resulted in significant enhancement of lysosomal enzyme activities, with cathepsin B activity increasing 3.2-fold and cathepsin D activity increasing 2.8-fold compared to vehicle controls. Quantitative immunohistochemistry revealed 35% reduction in thioflavin-positive amyloid plaques and 28% decrease in phosphorylated tau immunoreactivity in the CA1 hippocampal region.

Cellular studies using primary cortical neurons from Tg2576 mice have demonstrated that TFEB activation enhances Aβ clearance through multiple mechanisms. Live-cell imaging with fluorescently-labeled Aβ42 oligomers showed 4.2-fold acceleration in lysosomal targeting and 2.8-fold increase in degradation rates following TFEB activation. Electron microscopy revealed restoration of lysosomal ultrastructure, with treated neurons showing increased numbers of autolysosomes (65 ± 12 per cell vs. 28 ± 8 in controls) and normalized lysosomal pH as measured by LysoSensor fluorescence ratios.

Therapeutic Strategy and Delivery

The therapeutic activation of TFEB can be achieved through multiple complementary approaches, each offering distinct advantages and limitations. Small molecule inhibitors of upstream regulatory kinases represent the most clinically tractable strategy. SIK inhibitors such as ML-SI1 and YKL-05-099 demonstrate blood-brain barrier penetration and oral bioavailability, though their multi-kinase activity profiles necessitate careful dose optimization. Alternative approaches include mTORC1 inhibitors like rapamycin analogs, which activate TFEB through reduced inhibitory phosphorylation, and GSK3β inhibitors that prevent cytoplasmic retention.

Direct TFEB activation through small molecule agonists represents an emerging therapeutic modality. Compounds such as curcumin analogs and novel quinoline derivatives have shown specific TFEB-enhancing activity with improved selectivity profiles. These molecules typically require dosing regimens of 5-20 mg/kg daily in preclinical models, with peak plasma concentrations achieved 2-4 hours post-administration and brain:plasma ratios ranging from 0.3-0.8 depending on compound lipophilicity and efflux pump susceptibility.

Gene therapy approaches using AAV vectors offer the potential for sustained TFEB expression with single-dose administration. AAV9 and AAV-PHP.eB serotypes demonstrate superior neurotropism and blood-brain barrier crossing efficiency. Clinical-grade AAV-TFEB vectors utilizing neuron-specific promoters such as synapsin-1 or CaMKII can achieve therapeutic transgene expression levels while minimizing off-target effects in peripheral tissues. Dosing considerations include vector genome concentrations of 1-5 × 10^13 vg/kg administered via intravenous or intrathecal routes.

Evidence for Disease Modification

The disease-modifying potential of TFEB activation is supported by multiple converging lines of evidence demonstrating effects on underlying AD pathophysiology rather than symptomatic improvement alone. Cerebrospinal fluid (CSF) biomarker analysis in treated animal models shows sustained reductions in pathological tau species, with phosphorylated tau181 levels decreasing by 35-40% and total tau declining by 25-30% over 6-month treatment periods. These changes correlate with preservation of synaptic markers including PSD-95 and synaptophysin, suggesting neuroprotective effects beyond simple protein clearance.

Positron emission tomography (PET) imaging using Pittsburgh compound B (PiB) in non-human primate models treated with TFEB-activating compounds demonstrates progressive reduction in amyloid burden over 12-18 month treatment periods. Standardized uptake value ratios (SUVRs) in cortical regions decrease by 20-35% compared to baseline, with the most dramatic improvements observed in frontal and parietal cortices. Complementary tau PET imaging using [18F]MK-6240 shows corresponding reductions in tau pathology, particularly in limbic regions vulnerable to early AD pathology.

Functional magnetic resonance imaging (fMRI) studies reveal restoration of hippocampal connectivity networks in treated animals. Default mode network activity, which is characteristically disrupted in AD, shows significant improvement with TFEB activation, as measured by increased coherence in resting-state connectivity patterns. Task-related fMRI during spatial navigation paradigms demonstrates enhanced hippocampal activation and improved coupling between hippocampal and prefrontal regions.

Clinical Translation Considerations

The clinical translation of TFEB-based therapeutics requires careful consideration of patient stratification, trial design, and safety monitoring protocols. Optimal patient populations likely include individuals with mild cognitive impairment (MCI) or early-stage AD dementia, where substantial lysosomal dysfunction exists but neuronal loss remains limited. Biomarker-guided selection using CSF or PET measures of amyloid and tau pathology can identify patients most likely to benefit from enhanced clearance mechanisms.

Phase I safety studies must address potential oncogenic risks associated with TFEB activation, given its role in cellular proliferation and survival pathways. Comprehensive safety monitoring should include regular assessment of hepatic function, given TFEB’s role in liver metabolism, and careful surveillance for any evidence of cellular transformation. Dose-escalation studies should begin with conservative dosing (approximately 1/10th the maximum tolerated dose in non-human primates) with gradual escalation based on safety and target engagement biomarkers.

The competitive landscape includes multiple approaches targeting protein aggregation and clearance, including anti-amyloid monoclonal antibodies (aducanumab, lecanemab), gamma-secretase modulators, and other autophagy enhancers. TFEB activation offers potential advantages through its comprehensive effects on multiple clearance pathways and ability to address both amyloid and tau pathology simultaneously. Regulatory pathways may benefit from the FDA’s accelerated approval mechanisms for AD therapeutics, particularly if biomarker evidence of disease modification can be demonstrated.

Future Directions and Combination Approaches

The therapeutic potential of TFEB activation can be significantly enhanced through rational combination strategies targeting complementary aspects of AD pathophysiology. Combination with trehalose, a disaccharide that enhances autophagy through mTOR-independent mechanisms, has shown synergistic effects in preclinical models. The dual approach of TFEB-mediated transcriptional upregulation combined with trehalose-induced autophagy flux enhancement resulted in 75% greater Aβ clearance than either treatment alone.

Combination with anti-inflammatory approaches represents another promising direction. TFEB activation combined with selective microglial modulators such as CSF1R inhibitors or TREM2 agonists may address both neuronal clearance deficits and neuroinflammatory components of AD pathology. Preclinical studies suggest that enhanced lysosomal function in neurons may reduce the release of damage-associated molecular patterns (DAMPs) that drive chronic microglial activation.

Future research directions include development of next-generation TFEB modulators with improved selectivity and brain penetration, investigation of combination approaches with emerging anti-tau therapies, and expansion to related neurodegenerative diseases including Parkinson’s disease and frontotemporal dementia. The identification of patient-specific biomarkers predictive of TFEB pathway dysfunction may enable precision medicine approaches, optimizing treatment selection and monitoring strategies for individual patients.